Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of MOC.WA is 12 and suggests 101% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell